Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextran 10 is a highly purified, non-toxic, branched glucose polymer (polysaccharide) with an average molecular weight of approximately 10,000 Daltons (10 kDa). It is produced via fermentation of Leuconostoc bacteria and consists predominantly of α-1,6 glycosidic linkages with some α-1,3 branches, making it highly water-soluble and biocompatible. While dextrans are broadly used in various medical applications, including as plasma volume expanders and antithrombotic agents, the provided clinical trial context specifically highlights its investigation as a dietary supplement for its effect on post-prandial glucose response. It is also available as an active pharmaceutical ingredient (API) or excipient for use in drug products and medical devices.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dextran 10.